Literature DB >> 14506510

Analysis of the hypericin and pseudohypericin content of commercially available St John's Wort preparations.

Andrew H Draves1, Scott E Walker.   

Abstract

CONTEXT: The use of herbal medications and supplements has been growing worldwide with over four billion dollars a year spent on alternative medicines in the United States. St John's wort herbal preparations are generally standardized to "total hypericins" as a means of illustrating a degree of quality control to the consumer. This standardization has been based on a nonspecific method that overestimates and sums the two major naphthodianthrone compounds (hypericin and pseudohypericin) that are found in these products.
OBJECTIVE: To use a more specific and sensitive method to accurately determine the total hypericin content (sum of hypericin and pseudohypericin) in commercially available St John's wort herbal preparations.
DESIGN: The current standard method for determining the naphthodianthrone content is a spectrophotometric method specified in the United States Pharmacopeia. Compounds other than hypericin and pseudohypericin can contribute falsely to the naphthodianthrone concentration, reducing this methods specificity.
SETTING: Fifty-four commercially available St John's wort products were purchased in Canada and the United States. MAIN OUTCOME MEASURES: A specific and sensitive liquid chromatographic method with fluorescent detection was used to specifically quantify the hypericin and pseudohypericin content in commercially purchased St John's wort products.
RESULTS: Analysis revealed large variations in total naphthodianthrone content, with the percentage of label claim varying from 0% to 108.62% for capsules, and from 31.34% to 80.18% for tablets. The content of tinctures varied from zero to 118.58 microg/ml. Only two products were observed to have a total naphthodianthrone concentrations within 10% of their label claim.
CONCLUSIONS: When the active or marker compounds in an herbal or alternative medicine have been identified, standardization is an important step to ensure consistency from batch to batch. However, consistency is not apparent between brands and most products have inaccurate label claims. On average, most labels overestimate the hypericin and pseudohypericin content by a factor of almost two.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14506510

Source DB:  PubMed          Journal:  Can J Clin Pharmacol        ISSN: 1198-581X


  13 in total

1.  Highly variable contents of phenolics in St. John's Wort products affect their transport in the human intestinal Caco-2 cell model: pharmaceutical and biopharmaceutical rationale for product standardization.

Authors:  Song Gao; Wen Jiang; Taijun Yin; Ming Hu
Journal:  J Agric Food Chem       Date:  2010-06-09       Impact factor: 5.279

2.  St John's wort versus paroxetine for depression.

Authors:  Jane Jurcic; Jennifer A Pereira; Devon Kavanaugh
Journal:  Can Fam Physician       Date:  2007-09       Impact factor: 3.275

3.  The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose.

Authors:  Silke C Mueller; Jolanta Majcher-Peszynska; Bernhard Uehleke; Sebastian Klammt; Ralf G Mundkowski; Wolfram Miekisch; Hartwig Sievers; Steffen Bauer; Bruno Frank; Guenther Kundt; Bernd Drewelow
Journal:  Eur J Clin Pharmacol       Date:  2005-12-10       Impact factor: 2.953

4.  Mixtures research at NIEHS: an evolving program.

Authors:  Cynthia V Rider; Danielle J Carlin; Micheal J Devito; Claudia L Thompson; Nigel J Walker
Journal:  Toxicology       Date:  2012-11-09       Impact factor: 4.221

5.  No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers.

Authors:  Silke C Mueller; Jolanta Majcher-Peszynska; Ralf G Mundkowski; Bernhard Uehleke; Sebastian Klammt; Hartwig Sievers; Romanus Lehnfeld; Bruno Frank; Kerstin Thurow; Guenther Kundt; Bernd Drewelow
Journal:  Eur J Clin Pharmacol       Date:  2008-09-03       Impact factor: 2.953

Review 6.  Interaction of St John's wort with conventional drugs: systematic review of clinical trials.

Authors:  Edward Mills; Victor M Montori; Ping Wu; Keith Gallicano; Mike Clarke; Gordon Guyatt
Journal:  BMJ       Date:  2004-07-03

Review 7.  Cytochrome P450 enzyme mediated herbal drug interactions (Part 1).

Authors:  Sompon Wanwimolruk; Virapong Prachayasittikul
Journal:  EXCLI J       Date:  2014-04-02       Impact factor: 4.068

8.  National surveillance of herbal dietary supplement exposures: the poison control center experience.

Authors:  Brian M Gryzlak; Robert B Wallace; M Bridget Zimmerman; Nicole L Nisly
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-09       Impact factor: 2.890

9.  The effect of St John's wort on the pharmacokinetics of docetaxel.

Authors:  Andrew K L Goey; Irma Meijerman; Hilde Rosing; Serena Marchetti; Marja Mergui-Roelvink; Marianne Keessen; Jacobus A Burgers; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 5.577

Review 10.  Cytochrome P450 enzyme mediated herbal drug interactions (Part 2).

Authors:  Sompon Wanwimolruk; Kamonrat Phopin; Virapong Prachayasittikul
Journal:  EXCLI J       Date:  2014-08-20       Impact factor: 4.068

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.